Charles Cho is a Nephrology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
505 S Virgil Ave
Ste. 301
Los Angeles, CA 900201406
Telephone
213-674-8282Registry record last updated 13 Nov 2014.
Clinical trials
- Caffeine/Propranolol Intervention for Acute Migraine
Sponsor: Stanford University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
38 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20258 payments
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
45.4%Statin17.3%Atorvastatin Calcium91%Rosuvastatin Calcium6%Pravastatin Sodium1%Simvastatin1%Part D<11 patientsAngiotensin receptor blocker (ARB)11.3%Losartan Potassium72%Losartan-Hydrochlorothiazide19%Olmesartan Medoxomil5%Valsartan2%Olmesartan-Hydrochlorothiazide1%Valsartan-Hydrochlorothiazide1%Part D<11 patients+ 18 more classes in this area
Metabolism & gastrointestinal
28.4%Biguanide (metformin)6.6%Metformin Hcl95%Metformin Hcl Er5%Part D≥255 patientsSGLT2 inhibitor6.2%Jardiance79%Farxiga16%Invokana2%Synjardy2%Dapagliflozin1%Part D<11 patients+ 13 more classes in this area
Genitourinary & hormones
7.6%alpha-Adrenergic Blocker3.9%Tamsulosin Hcl100%Part D≥169 patients5-alpha Reductase Inhibitor2.2%Finasteride100%Part D≥90 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2010–2010 per NIH RePORTER. The latest:
- Screen for Small Molecule Regulators of Retinal Progenitor Epithelial Cell Phagoc
Novartis Inst for Functional Genomics
FY2010$161,000R21NS071545
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”